How many 8-K filings has Iovance Biotherapeutics, Inc. filed?

Iovance Biotherapeutics, Inc. (IOVA) has 30 8-K (Current Event Report) filings on record, spanning Jan 2024 to Aug 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Iovance Biotherapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Iovance Biotherapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Iovance Biotherapeutics, Inc. (IOVA) — 8-K Filings

All 8-K filings from Iovance Biotherapeutics, Inc.. Browse 30 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (30)

IOVANCE BIOTHERAPEUTICS, INC. Files 8-K — Aug 29, 2025 Risk: low
On August 29, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific materia
IOVANCE BIOTHERAPEUTICS, INC. Files 8-K for Material Agreement — Aug 22, 2025 Risk: medium
On August 22, 2025, IOVANCE BIOTHERAPEUTICS, INC. entered into a material definitive agreement. The company, incorporated in Delaware with EIN 753254381, is inv
IOVANCE BIOTHERAPEUTICS, INC. Files 8-K — Aug 19, 2025 Risk: low
On August 18, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spe
IOVANCE BIOTHERAPEUTICS Files 8-K on Operations, Personnel Changes — Aug 7, 2025 Risk: medium
On August 7, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing significant corporate events. The filing includes information on the company's re
IOVANCE BIOTHERAPEUTICS: Board and Officer Changes Reported — Jul 15, 2025 Risk: medium
On July 15, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes the
IOVANCE BIOTHERAPEUTICS: Board Changes & Executive Compensation Updates — Jul 3, 2025 Risk: medium
On June 30, 2025, IOVANCE BIOTHERAPEUTICS, INC. announced changes in its board of directors and executive compensation. Specifically, the company elected two ne
IOVANCE BIOTHERAPEUTICS: Board & Executive Changes Announced — Jun 13, 2025 Risk: medium
On June 10, 2025, IOVANCE BIOTHERAPEUTICS, INC. announced changes to its board of directors and executive compensation. The company filed a Form 8-K detailing t
IOVANCE BIOTHERAPEUTICS Files 8-K on Security Holder Vote — Jun 10, 2025 Risk: medium
On June 10, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report to announce a submission of matters to a vote of its security holders. The filing does not d
IOVANCE BIOTHERAPEUTICS Files 8-K on Financials — May 8, 2025 Risk: low
On May 8, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
IOVANCE BIOTHERAPEUTICS Files 8-K on Financials — Feb 27, 2025 Risk: low
On February 27, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing results of operations and financial condition. The filing also includes financ
IOVANCE BIOTHERAPEUTICS Files 8-K — Feb 10, 2025 Risk: low
On February 10, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or
IOVANCE BIOTHERAPEUTICS, INC. Enters and Terminates Agreements — Nov 21, 2024 Risk: medium
On November 15, 2024, IOVANCE BIOTHERAPEUTICS, INC. entered into a material definitive agreement and terminated another. The company, incorporated in Delaware,
IOVANCE BIOTHERAPEUTICS Files 8-K — Nov 8, 2024 Risk: low
On November 7, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing indicates that the company is an emerging growth company and has elected not
IOVANCE BIOTHERAPEUTICS Files 8-K on Financials — Nov 7, 2024 Risk: medium
On November 7, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing its financial results and operations. The filing provides information on the co
IOVANCE BIOTHERAPEUTICS APPOINTS NEW CHIEF MEDICAL OFFICER — Aug 9, 2024 Risk: medium
On August 8, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing the appointment of Dr. Frederick "Fritz" Morgan as Chief Medical Officer, effecti
IOVANCE BIOTHERAPEUTICS Files 8-K on Financials — Aug 8, 2024 Risk: medium
On August 8, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial
IOVANCE BIOTHERAPEUTICS FILES 8-K — Jun 28, 2024 Risk: low
On June 28, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disc
IOVANCE BIOTHERAPEUTICS Files 8-K on Security Holder Vote — Jun 11, 2024 Risk: low
On June 11, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, formerly know
IOVANCE BIOTHERAPEUTICS Files 8-K — Jun 3, 2024 Risk: low
On May 31, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is in
IOVANCE BIOTHERAPEUTICS APPOINTS NEW CHIEF MEDICAL OFFICER — May 24, 2024 Risk: medium
On May 23, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing the appointment of Dr. Frederick Vogt as Chief Medical Officer, effective May 20, 2
IOVANCE BIOTHERAPEUTICS Files 8-K on Financials — May 9, 2024 Risk: low
On May 9, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing results of operations and financial condition. The filing includes financial stateme
IOVANCE BIOTHERAPEUTICS Files 8-K — Apr 3, 2024 Risk: low
On April 3, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indic
IOVANCE BIOTHERAPEUTICS Files 8-K: Board & Executive Changes — Mar 29, 2024 Risk: medium
On March 26, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes
IOVANCE BIOTHERAPEUTICS FILES 8-K — Mar 4, 2024 Risk: low
On March 4, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
IOVANCE BIOTHERAPEUTICS Files 8-K on Other Events and Financials — Feb 29, 2024 Risk: low
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 28, 2024, reporting on "Other Events" and "Financial Statements and Exhibits." The filing indicates a cur
Iovance Biotherapeutics Files 8-K on Financial Condition — Feb 28, 2024 Risk: low
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 28, 2024, regarding its financial condition and results of operations. The filing indicates the company's
Iovance Biotherapeutics Files 8-K for Other Events and Exhibits — Feb 22, 2024 Risk: low
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 22, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a curren
Iovance Bio Files 8-K on Operations and Financial Condition — Feb 20, 2024 Risk: medium
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 20, 2024, reporting an event that occurred on February 16, 2024. The filing indicates that the company, i
IOVANCE Files 8-K for Simultaneous Communication Obligations — Jan 26, 2024
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on January 26, 2024, reporting an event that occurred on January 25, 2024. This filing indicates that the company is
IOVANCE BIOTHERAPEUTICS Files 8-K for 'Other Events' & Exhibits — Jan 8, 2024
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on January 8, 2024, indicating that it is using this filing for 'Other Events' and 'Financial Statements and Exhibits

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX